B-type natriuretic peptide and high sensitive C-reactive protein predict 2-year all cause mortality in chest pain patients: a prospective observational study from Salta, Argentina

BMC Cardiovascular Disorders

Volumn 11, Issue , 2011, Pages

  León De La Fuente, Ricardo ^a,b   Naesgaard, Patrycja A ^b   Nilsen, Stein T ^b,c   Woie, Leik ^b   Aarsland, Torbjoern ^b   Gallo, Patricio ^a   Grundt, Heidi ^b,c   Staines, Harry ^d   Nilsen, Dennis W T ^b,c  

^a Universidad Catolica de Salta   (Argentina)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d Sigma Statistical Services   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARGENTINA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THORAX PAIN; UPREGULATION;

EID: 80053172399     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-11-57     Document Type: Article

References (36)

1. Bassand JP, Hamm WC, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KAA, Hasdai D, Magnus Ohman E, Wallentin L, Wijns W. Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation. ESC Clinical Practice Guidelines. Eur Heart J 2007, 28:1598-1660.
2. Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, Park HS, Cho Y, Chae SC, Jun JE, Park WH. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J 2006, 70:1379-84. 10.1253/circj.70.1379, 17062957.
3. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C reactive protein, and B-type natriuretic peptide. Circulation 2002, 105:1760-3. 10.1161/01.CIR.0000015464.18023.0A, 11956114.
4. Ndrepepa G, Kastrati A, Braun S, Mehilli J, Niemoller K, von BN, von BO, Vogt W, Schomig A. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. Am J Med 2006, 119:355-8.
5. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998, 135:825-32. 10.1016/S0002-8703(98)70041-9, 9588412.
6. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995, 96:1280-7. 10.1172/JCI118162, 185749, 7657802.
7. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003, 107:2786-92. 10.1161/01.CIR.0000070953.76250.B9, 12771003.
8. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-21. 10.1056/NEJMoa011053, 11586953.
9. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, Dibattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003, 41:1264-72. 10.1016/S0735-1097(03)00168-2, 12706919.
10. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002, 106:2913-8. 10.1161/01.CIR.0000041661.63285.AE, 12460871.
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-26. 10.1056/NEJM199901143400207, 9887164.
12. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331:417-24. 10.1056/NEJM199408183310701, 7880233.
13. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990, 65:168-72. 10.1016/0002-9149(90)90079-G, 2296885.
14. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-9. 10.1161/01.CIR.0000053730.47739.3C, 12551853.
15. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002, 105:2019-23. 10.1161/01.CIR.0000015507.29953.38, 11980679.
16. de Lemos JA. The latest and greatest new biomarkers: which ones should we measure for risk prediction in our practice?. Arch Intern Med 2006, 166:2428-30. 10.1001/archinte.166.22.2428, 17159006.
17. Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med 2006, 166:2455-60. 10.1001/archinte.166.22.2455, 17159010.
18. The GRACE Investigators. GRACE (Global Registry of Acute Coronary Events): a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001, 141:190-9. 10.1067/mhj.2001.112404, 11174331.
19. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967, 20:457-64. 10.1016/0002-9149(67)90023-9, 6059183.
20. Muller-Bardorff M, Hallermayer K, Schroder A, Ebert C, Borgya A, Gerhardt W, Remppis A, Zehelein J, Katus HA. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem 1997, 43:458-66.
21. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. JAm Coll Cardiol 2002, 40:437-45.
22. Kavsak PA, MacRae AR, Newman AM, Lustig V, Palomaki GE, Ko DT, Tu JV, Jaffe AS. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of longterm mortality and heart failure. Clin Biochem 2007, 40:326-9. 10.1016/j.clinbiochem.2006.10.025, 17292342.
23. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000, 284:835-42. 10.1001/jama.284.7.835, 10938172.
24. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000, 101:2557-67.
25. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to longterm mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000, 343:1139-47. 10.1056/NEJM200010193431602, 11036119.
26. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE, Califf RM, Topol EJ, Lee KL, . for the GUSTO-IIa Investigators Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia. N Engl J Med 1996, 335:1333-1342. 10.1056/NEJM199610313351801, 8857016, for the GUSTO-IIa Investigators.
27. Newby LK, Goldmann BU, Ohman EM. Troponin: An important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2003, 41:31-36.
28. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005, 6(2):21-9. 10.1016/j.atherosclerosissup.2005.02.005, 16275166.
29. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002, 89:463-5. 10.1016/S0002-9149(01)02271-8, 11835931.
30. Olsen MH, Christensen MK, Hansen TW, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jorgensen T, Hildebrandt P. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. J Hypertens 2006, 24:655-61. 10.1097/01.hjh.0000217847.03208.ba, 16531793.
31. de Winter RJ, Stroobants A, Koch KT, Bax M, Schotborgh CE, Mulder KJ, Sanders GT, van Straalen JP, Fischer J, Tijssen JG, Piek JJ. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am J Cardiol 2004, 94:1481-5. 10.1016/j.amjcard.2004.08.023, 15589000.
32. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J, Munzel T, Cambien F, Tiret L, Blankenberg S. Analysis of N-terminal- pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005, 26:241-9.
33. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003, 108:275-81. 10.1161/01.CIR.0000079170.10579.DC, 12847065.
34. James SK, Lindback J, Tilly J, Siegbahn A, Venge P, Armstrong P, Califf R, Simoons ML, Wallentin L, Lindahl B. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 2006, 48:1146-54. 10.1016/j.jacc.2006.05.056, 16978997.
35. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-7. 10.1056/NEJMoa020233, 12124404.
36. Brugger-Andersen T, Ponitz V, Staines H, Pritchard D, Grundt H, Nilsen DWT. B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac event in chest pain patient: a prognostic study. BMC Cardiovascular Disorders 2008, 8(1):34. 10.1186/1471-2261-8-34, 2628862, 19032759.